The Founder of Singmed-Mr. Albert Zhao Was Invited to Attend the China Pharmaceutical Industrial Pharmaceutics Conference 2023
China Pharmaceutical Industrial Pharmaceutics Conference 2023 was held in Nanjing, Jiangsu Province from December 15th to 17th. The conference invited experts and scholars in related fields of industrial pharmacy to conduct academic discussions on technological innovation and transformation and application of novel and complex preparations, providing an exchange platform for the upstream and downstream of the industrial chain such as high-end preparations, complex preparations and their key auxiliary materials, production equipments and advanced manufacturing technology.
As a leading innovative design, development and manufacturing enterprise of drug delivery devices in China, as well as the only domestic professional enterprise focusing on the development of complex devices, Mr. Albert Zhao, founder of Suzhou Singmed Medical Device Science & Technology Ltd., was invited to attend the meeting.
A brief introduction to The Best Practice of Inhalation Soft Mist Device Development
During the meeting, Mr. Albert Zhao shared the experience, inspiration and achievements of Singmed from its initial development to today's scale in the past few years - " The Best Practice of Inhalation Soft Mist Device Development" :
Soft Mist Inhaler
●The pocket-sized device of SMI is designed to deliver a one-breath inhalable aerosol, aiming to optimize drug delivery efficiency to the lungs, minimize patient coordination and inspiratory force requirements, and enhance patient experience and convenience.
● Utilizing an innovative aerosol technology, this device converts a drug solution into a soft mist consisting of two rotating liquid jets that pass through each other via a precisely-designed two-channel nozzle. This unique soft mist exhibits characteristics such as low velocity, high cohesion, long residence time, and small particle size, which facilitate effective distribution of drugs in the lungs.
● Compared with other inhalers, SMI offers several advantages over others in terms of pulmonary deposition rate, oropharyngeal deposition rate, regional distribution, dose consistency, respiratory parameters, and patient satisfaction. By improving drug deposition in specific areas of the lungs like small airways, this device enhances treatment effectiveness while reducing potential side effects.
Soft mist inhaler is a great product combined of complex parts design with high-precision and high-performance materials, silicon microfluidic chip atomization mechanism and proficient precise injection process. Equipped with fully automated production lines and assembly lines that continuously produce millions of parts, Singmed has overcome the first challenge in the transformation of SMI development practices to industrialization - the large-scale production of complex drug delivery devices.
Photo of Atomizing Chips
The manufacture of silicon based microfluidic atomization chips is the process aesthetics of semiconductor processing on the drug delivery device, which needs to reach 100% qualified rate of the finished products.
Rigorous Management Process: Support Project Development
Finally, Mr. Albert Zhao stressed that a scientific project management process is a necessary condition for achieving excellent drug delivery device development results:
● The project development of inhalation drug delivery devices should not only be result-oriented, but should pay more attention to process, and guide the right results through scientific and rigorous R&D engineering management process.
● Precision industry, there is no fast and economy and it requires a lot of manpower, financial resources, material resources and time investment. Singmed will adhere to long-term doctrine and maintain professionalism.
